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Abstract 
Background: More than 30,000 malaria cases are reported annually among international travellers. Despite improve‑
ments in malaria control, malaria continues to threaten travellers due to inaccurate perception of risk and sub‑optimal 
pre‑travel preparation.
Methods: Records with a confirmed malaria diagnosis after travel from January 2003 to July 2016 were obtained 
from GeoSentinel, a global surveillance network of travel and tropical medicine providers that monitors travel‑related 
morbidity. Records were excluded if exposure country was missing or unascertainable or if there was a concomitant 
acute diagnosis unrelated to malaria. Records were analyzed to describe the demographic and clinical characteristics 
of international travellers with malaria.
Results: There were 5689 travellers included; 325 were children <18 years. More than half (53%) were visiting friends 
and relatives (VFRs). Most (83%) were exposed in sub‑Saharan Africa. The median trip duration was 32 days (interquar‑
tile range 20–75); 53% did not have a pre‑travel visit. More than half (62%) were hospitalized; children were hospital‑
ized more frequently than adults (73 and 62%, respectively). Ninety‑two per cent had a single Plasmodium species 
diagnosis, most frequently Plasmodium falciparum (4011; 76%). Travellers with P. falciparum were most frequently VFRs 
(60%). More than 40% of travellers with a trip duration ≤7 days had Plasmodium vivax. There were 444 (8%) travellers 
with severe malaria; 31 children had severe malaria. Twelve travellers died.
Conclusion: Malaria remains a serious threat to international travellers. Efforts must focus on preventive strate‑
gies aimed on children and VFRs, and chemoprophylaxis access and preventive measure adherence should be 
emphasized.
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Background
An estimated 214 million infections and 438,000 deaths 
attributed to malaria occurred globally in 2015 [1]. 
Although there have been improvements in global malaria 
control since 2000, malaria remains a threat to inter-
national travellers. Malaria is endemic throughout the 
tropics and sub-tropics, regions visited by an estimated 
25–30 million international travellers annually [2], result-
ing in an estimated 30,000 travel-related malaria infec-
tions [3]. Imported malaria may occur more often along 
certain travel routes in these areas, and may result in sec-
ondary transmission [4] if the infection is brought back 
to a non-endemic country. Most of the reported 17,471 
imported malaria infections among US travellers from 
2004 to 2014 were acquired while travelling in Africa; 
Plasmodium falciparum or Plasmodium vivax comprised 
the majority of infections [5]. Most P. falciparum expo-
sures cluster in Africa and the Caribbean (Hispaniola) 
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and P. vivax exposures occur most frequently in Central 
America, South America, Asia, and Oceania [4].
Despite the risk of malaria when travelling to an endemic 
country, and the ability to prevent malaria with proper 
chemoprophylaxis and mosquito-bite precautions, most 
international travellers do not have a pre-travel clinical 
visit with a healthcare provider [6]. However, even among 
travellers who do receive pre-travel care, some may be 
non-adherent to chemoprophylaxis due to forgetfulness 
or medication side-effects, or they may decline to take 
chemoprophylaxis due to cost, peer advice or low per-
ceived risk [7]. Furthermore, travellers may be prescribed a 
medication ineffective for the intended travel area [5]. The 
increasing connectivity of malaria-endemic countries with 
non-endemic countries via air travel [4, 8], the lack of ade-
quate pre-travel preparation, and personal behaviour that 
may increase Anopheles mosquito exposure [9] may keep 
malaria as a continued threat to travellers’ health.
The purpose of this analysis is to describe the demo-
graphic characteristics, trip details, clinical visit informa-
tion, and disease attributes of travellers diagnosed with 
malaria at GeoSentinel Global Surveillance Network sites 
following travel to malaria-endemic areas.
Methods
Data source
GeoSentinel, a global clinician-based sentinel surveil-
lance system of 66 specialized travel and tropical medi-
cine clinics, monitors infectious diseases and other 
travel-related conditions among international travellers 
and migrants [10]. It was established in 1995 as a col-
laboration between the Centers for Disease Control and 
Prevention (CDC) and the International Society of Travel 
Medicine. All sites have experience of diagnosing and 
treating patients with travel-related infectious diseases 
and contribute systematic surveillance data on patients 
seen for a travel-related illness [10, 11]. Most sites are 
affiliated with academic medical centres [11], and are 
located in 29 countries: 23 sites in Europe, 25 in the USA 
or Canada, 10 in Asia or Australasia, 3 in Latin America, 
2 in Africa, and 2 in the Middle East. Diagnostic confir-
mation and Plasmodium speciation are based on the best 
reference diagnostic test(s) available in that country, and 
final diagnosis coding is at a clinician’s discretion. Analy-
sis of GeoSentinel surveillance data has been approved as 
non-research by a CDC human subjects advisor.
Inclusion and exclusion criteria
The records of international travellers with a ‘confirmed’ 
malaria diagnosis (those made by an indisputable diag-
nostic test) seen at a GeoSentinel site after travel comple-
tion from 1 January, 2003 to 30 July, 2016 were examined. 
Records with a ‘probable’ malaria diagnosis (supported 
by evidence strong enough to establish presumption 
but not proof), a missing or unascertainable country of 
exposure, or an additional acute diagnosis not related to 
malaria (e.g., dengue) were excluded.
Data extraction and definitions
Data were extracted on traveller demographics, trip 
details, clinical visit information (including if a traveller 
received a pre-travel visit with a healthcare provider), 
and disease attributes. Malaria was defined as ‘severe’ if 
the record included a diagnosis code for ‘severe and com-
plicated malaria’ or ‘cerebral malaria’. GeoSentinel desig-
nations of ‘severe and complicated malaria’ and ‘cerebral 
malaria’ are defined using World Health Organization 
(WHO) classifications [12], and are assigned at a clini-
cian’s discretion.
Statistical analysis
Data were managed using Microsoft Access. All analyses 
were descriptive and were performed using SAS version 
9.4 (Cary, NC, USA).
Results
All travellers with a malaria diagnosis
There were 5689 travellers diagnosed with malaria 
included in the analysis (Fig. 1), including 325 children 
<18 years of age. The overall median age was 37 years 
(range 0–88) and 69% were male. Fifty-three per cent 
(2891 of 5421) of travellers with information available 
did not have a pre-travel visit (Table  1). More than 
half (53%) were travellers visiting friends and rela-
tives (VFRs). Eighty per cent of children were VFRs 
(Table  2); 167 (65%) of the 257 children VFRs were 
born in the country their parents immigrated to and 
231 (90%) travelled to sub-Saharan Africa. Business 
travel and tourism accounted for 17 and 16% of travel, 
respectively. Most travellers (83%) were exposed to 
malaria in sub-Saharan Africa, with malaria infection 
most frequently occurring after travel to Ghana (9%), 
Nigeria (8%) or Côte d’Ivoire (8%). The median trip 
duration was 32 days [interquartile range (IQR) 20–75]; 
600 (11%) travellers had a trip duration ≤7 days. Chil-
dren were hospitalized more frequently than adults (73 
and 62% respectively) (Table 2).
Travellers with a single Plasmodium species diagnosis
A single Plasmodium species was reported in 5246 (92%) 
travellers: Plasmodium falciparum in 4011 (76%), Plas-
modium vivax in 857 (16%), Plasmodium ovale in 251 
(5%), Plasmodium malariae in 124 (2%), and Plasmo-
dium knowlesi in 3 (<1%) (Table 1).
Among travellers with P. falciparum, the most frequent 
travel reason was VFR (60%), and most were exposed in 
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sub-Saharan Africa (94%) (Table 1). The median number 
of days between return from travel and presenting at a 
GeoSentinel site was shortest for P. falciparum (10 days, 
IQR 5–16). Sixty-three per cent of travellers with P. falci-
parum were hospitalized, and 57% (2173 of 3843) of trav-
ellers with information available did not have a pre-travel 
visit; 68% of VFRs with P. falciparum did not have a pre-
travel visit. Military travellers with P. falciparum had the 
longest median trip duration (107 days, IQR 46–132) and 
VFRs and tourists with P. falciparum had the shortest 
median trip duration (31  days, IQR 21–58 and 24  days, 
IQR 14–42 days, respectively).
Travellers acquired vivax malaria most frequently in 
South Central Asia (32%), with 30% having travelled to 
either India or Pakistan. Plasmodium vivax also caused 
the majority of malaria in those who travelled to other 
regions of Asia, the Americas, Oceania, and North 
Africa. Of 176 military travellers with a single Plas-
modium species diagnosis, the majority of whom were 
French, 108 (61%) had P. vivax. Among travellers with 
a single Plasmodium species diagnosis, more than 40% 
with a trip duration ≤7  days and 14% with a trip dura-
tion >7  days had P. vivax. VFRs who travelled to South 
Central Asia accounted for 23% of the 228 travellers with 
P. vivax who had a trip duration ≤7 days.
Only 29% (69 of 239) of travellers with information 
available with P. ovale single species infections did not 
have a pre-travel visit, and sub-Saharan Africa was the 
Met inclusion criteria
n= 5,689 (90%) 
GeoSentinel malaria 
records
n= 6,300 
P. falciparum
n= 4,011 (76%)
P. vivax
n= 857 (16%)
P. ovale 
n= 251 (5%)
P. malariae 
n= 124 (2%)
P. knowlesi 
n= 3 (<1%)
Did not have a single 
Plasmodium species 
diagnosis 
n= 443 (8%) 
Missing or 
unascertainable country
n= 314 (5%)
Additional acute 
diagnosis not related to 
malaria
n= 297 (5%)
Single Plasmodium
species diagnosis
n= 5,246 (92%)
Fig. 1 Number of malaria records from GeoSentinel meeting the exclusion and inclusion criteria, and species diagnoses for included cases, January 
2003–June 2016
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most frequent exposure region for travellers with P. ovale 
(97%). The median trip duration and median number of 
days between returning and visiting a GeoSentinel site 
were longest for P. ovale, at 56  days (IQR 22–156) and 
52 days (IQR 16–98), respectively.
Travellers with a mixed Plasmodium infection
Sixty-six (1%) travellers had a mixed infection with P. 
falciparum and P. vivax (26 travellers; 39%), P. falcipa-
rum and P. ovale (21 travellers; 32%), P. falciparum and 
P. malariae (15 travellers; 23%), P. vivax and P. ovale (3 
Table 1 Characteristics of travellers with malaria reported to GeoSentinel, January 2003–June 2016
a Information was not available for 47 travellers (2 with P. falciparum)
b Information was not available for 268 travellers (168 with P. falciparum, 59 with for P. vivax, 14 with P. ovale, 5 with P. malariae, and 1 with P. knowlesi)
c Information was not available for 4 travellers (3 with P. falciparum and 1 with P. vivax)
d Includes missionaries, volunteers and aid workers
e Information was not available for 1 traveller with P. falciparum
Characteristic All travellers 
(n = 5689)
No species diag-
nosis (n = 443)
P. falciparum 
(n = 4011)
P. vivax 
(n = 857)
P. ovale 
(n = 251)
P. malariae 
(n = 124)
P. knowlesi 
(n = 3)
Median age, years 
(range)
37 (0–88) 38 (0–87) 30 (1–88) 36 (2–73) 39 (4–76) 40 (35–52)
Male, n (%)a 3918 (69) 304 (69) 2712 (68) 632 (74) 179 (71) 89 (72) 2 (67)
Travellers without 
pre‑travel visit, 
n (%)b
2891 (53) 229 (54) 2173 (57) 373 (47) 69 (29) 46 (39) 1 (50)
Reason for travel, n (%)c
 VFRs 3017 (53) 178 (40) 2422 (60) 277 (32) 90 (36) 50 (40) 0 (0)
 Business 967 (17) 124 (26) 623 (16) 127 (15) 60 (24) 32 (26) 1 (33)
 Tourism 918 (16) 87 (20) 530 (13) 247 (29) 34 (14) 19 (15) 1 (33)
 Missionaryd 514 (9) 49 (11) 330 (8) 74 (9) 40 (16) 20 (16) 1 (33)
 Military 184 (3) 8 (2) 44 (1) 108 (13) 23 (9) 1 (1) 0 (0)
 Student 77 (1) 6 (1) 50 (1) 18 (2) 1 (<1) 2 (2) 0 (0)
 Migrant worker 11 (<1) 0 (0) 7 (<1) 2 (<1) 2 (1) 0 (0) 0 (0)
 Planned medical 
care
4 (<1) 1 (<1) 2 (<1) 1 (<1) 0 (0) 0 (0) 0 (0)
 Research 3 (<1) 0 (0) 0 (0) 2 (0.2) 1 (<1) 0 (0) 0 (0)
Region of exposure, n (%)
 Sub‑Saharan 
Africa
4705 (83) 404 (91) 3771 (94) 167 (20) 244 (97) 119 (96) N/A
 South Central 
Asia
309 (5) 6 (1) 28 (1) 272 (32) 2 (1) 1 (1) N/A
 Southeast Asia 266 (5) 17 (4) 112 (3) 133 (15) N/A 1 (1) 3 (100)
 South America 195 (3) 6 (1) 16 (<1) 171 (20) 1 (<1) 1 (1) 0 (0)
 Oceania 96 (2) 3 (1) 13 (<1) 77 (9) 2 (1) 1 (1) 0 (0)
 Caribbean 45 (1) 2 (<1) 42 (1) 1 (<1) 0 (0) 0 (0) 0 (0)
 North Africa 39 (1) 2 (<1) 26 (1) 8 (1) 2 (1) 1 (1) 0 (0)
 Central America 30 (<1) 3 (1) 2 (<1) 25 (3) 0 (0) 0 (0) 0 (0)
 Northeast Asia 3 (<1) 0 (0) 0 (0) 3 (<1) 0 (0) 0 (0) 0 (0)
 Middle East 1 (<1) 0 (0) 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0)
Median trip dura‑
tion, days (IQR)
32 (20–75) 31 (17–76) 31 (20–63) 36 (18–101) 56 (22–156) 34 (26–95) 21 (21–52)
Median days 
between return 
and presenting 
to a site (IQR)
11 (6–21) 10 (5–17) 10 (5–16) 30 (13–76) 52 (16–98) 35 (15–64) 21 (2–23)
Hospitalized, n 
(%)e
3523 (62) 345 (78) 2537 (63) 477 (56) 105 (41) 59 (48) 0 (0)
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travellers; 5%), or P. vivax and P. malariae (1 travel-
ler; 1%) (Table 3). Most travellers with mixed infections 
did not receive a pre-travel visit (34 of 58 travellers with 
information available; 59%), travelled to sub-Saharan 
Africa (79%), and were VFRs (52%); more than 60% were 
hospitalized.
Travellers with severe malaria
Of the 444 (8%) travellers meeting the WHO definition 
for severe malaria, more than half [246 of 429 (57%) of 
travellers with information available] did not have a 
pre-travel visit; most (95%) travelled to sub-Saharan 
Africa, and the most frequent reason for travel was VFR 
(42%) (Table 4). There were 124 single Plasmodium spe-
cies diagnoses: 97% were P. falciparum, 2% P. vivax and 
2% P. malariae. Thirty-one (10%) of the 325 children in 
this analysis had severe malaria; children younger than 
5 years of age accounted for almost half (42%) of the 31 
severe paediatric cases. Fourteen travellers, all adults, 
had cerebral malaria; all had trip durations >7 days and, 
per GeoSentinel records, none died. Only five (36%) 
travellers with cerebral malaria had a species diagnosis 
recorded; all were P. falciparum.
Five of 12 travellers who died had a species diagnosis; 
all were P. falciparum. The median age of deceased travel-
lers was 44 years (range 26–66); 55% (6 of 11) of travellers 
Table 2 Characteristics of  children <18  years of  age with  malaria reported to  GeoSentinel, January 2003–June 2016 
(n = 325)
a Three children were <1 year old; all were VFRs who travelled to sub-Saharan Africa and acquired P. falciparum
b Information was not available for 9 children (1 child 1–5 years of age, 2 children 6–11 years of age, and 6 children 12–17 years of age)
c Information was not available for 3 children, all 12–17 years of age
d Includes missionaries, volunteers and aid workers
e Information was not available for 20 children (9 children 1–5 years of age, 4 children 6–11 years of age, and 7 children 12–17 years of age)
f  Of these, 167 (65%) were born in the country their parents immigrated to
Characteristic All children (n = 325) 0–5  yearsa (n = 111) 6–11 years (n = 86) 12–17 years (n = 128)
Median age, years (range) 8 (4–15) 3 (2–4) 8 (7–10) 16 (14–17)
Male, n (%) 185 (57) 54 (49) 49 (57) 83 (65)
Travellers without pre‑travel visit, n (%)b 166 (53) 56 (51) 45 (54) 65 (53)
Reason for travel, n (%)c
 VFR 257 (80) 88 (80) 83 (97) 86 (69)
 Tourism 45 (14) 20 (18) 2 (2) 23 (18)
 Business 8 (2) 2 (2) 1 (1) 5 (4)
 Missionaryd 6 (2) 1 (1) 0 (0) 5 (4)
 Student 6 (2) 0 (0) 0 (0) 6 (5)
Region of exposure, n (%)
 Sub‑Saharan Africa 274 (84)e 100 (90) 72 (84) 102 (79)
 South Central Asia 35 (11) 10 (9) 13 (15) 12 (9)
 Southeast Asia 9 (3) 0 (0) 0 (0) 9 (7)
 North Africa 2 (1) 1 (1) 0 (0) 1 (1)
 Oceania 2 (1) 0 (0) 0 (0) 2 (2)
 South America 2 (1) 0 (0) 0 (0) 2 (2)
 Caribbean 1 (<1) 0 (0) 1 (1) 0 (0)
Plasmodium species, n (%)f
 P. falciparum 237 (78) 86 (84) 63 (77) 88 (73)
 P. vivax 46 (15) 10 (10) 14 (17) 22 (18)
 P. ovale 15 (5) 4 (4) 5 (6) 6 (5)
 P. malariae 7 (2) 2 (2) 0 (0) 5 (4)
 P. knowlesi 0 (0) 0 (0) 0 (0) 0 (0)
Median trip duration, days (IQR) 43 (29–90) 42 (28–85) 57 (35–89) 42 (28–108)
Median days between return and presenting to a site 
(IQR)
12 (6–22) 13 (6–25) 11 (7–20) 12 (6–23)
Hospitalized, n (%) 237 (73) 88 (79) 66 (77) 83 (65)
Severe malaria, n (%) 31 (10) 13 (12) 10 (12) 8 (6)
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with information available had a pre-travel visit; 92% were 
exposed in sub-Saharan Africa. Half were business travel-
lers. The median trip duration was 31 days (IQR 15–94).
Discussion
GeoSentinel, a specialized surveillance network, captured 
surveillance data from travel medicine facilities around 
the world and facilitated the description of malaria cases 
among returned travellers. The WHO’s World Malaria 
Report 2015 indicated that malaria infections, mostly 
involving persons living in endemic areas, declined by 
an estimated 18% from 2000 to 2015 [1]. Efforts to elimi-
nate malaria contributed to this decline, and the WHO’s 
Global Technical Strategy for Malaria 2016–2030 aspires 
to continue reducing malaria incidence and mortality by 
90% in high-burden countries [1, 13]. Despite improve-
ments in malaria control, imported malaria to the USA 
has increased since 1973 [5] and stabilized in the UK 
[14]. These data, together with GeoSentinel data, indicate 
that malaria continues to pose a health risk to travellers 
and surveillance of global travel-related malaria infec-
tion is essential to travellers’ health, as well as elimination 
efforts.
Specific traveller groups may more frequently acquire 
malaria while abroad than others [6]. Males were more 
frequently diagnosed with malaria than females; males 
are thought to be at higher risk of malaria [15], possi-
bly from higher travel frequency or increased exposure 
to mosquito bites from various activities [16]. However, 
women, children or migrants from high-burden coun-
tries may share a similar malaria infection frequency 
as men, but did not receive care at GeoSentinel sur-
veillance sites. Travellers with malaria more frequently 
acquired infection in sub-Saharan Africa than other 
regions. Sub-Saharan Africa remains the most heavily 
concentrated region for malaria transmission and, likely, 
traveller exposure [1]. The majority of the malaria bur-
den and malaria deaths worldwide are from 15 African 
countries [1]; Nigeria and the Democratic Republic of 
the Congo accounted for approximately 40% of malaria 
mortality per WHO in recent years [13]. Although the 
12 deaths were not exposed to malaria in these two 
countries, 11 (92%) were exposed in other countries in 
West or Central Africa. Malaria was also more frequent 
among VFRs than tourists, business travellers, or other 
Table 3 Region of  exposure for  travellers with  a mixed Plasmodium infection reported to  GeoSentinel, January 2003–
June 2016 (n = 66)
a One traveller had severe malaria
Plasmodium species n (%) Region(s) of exposure (n)
P. falciparum and P. vivax 26 (39) Sub‑Saharan Africa (15), Southeast Asia (9), South America (1), Central Asia (1)
P. falciparum and P. ovale 21 (32) Sub‑Saharan Africa (21)
P. falciparum and P. malariae 15 (23) Sub‑Saharan Africa  (14a), Oceania (1)
P. vivax and P. ovale 3 (5) Sub‑Saharan Africa (2), Oceania (1)
P. vivax and P. malariae 1 (1) South America (1)
Total 66
Table 4 Characteristics of  travellers with  severe malaria 
reported to  GeoSentinel, January 2003–June 2016 
(n = 444)
a Includes missionaries, volunteers and aid workers
Characteristic
Median age, years (range) 42 (1–88)
Male, n (%) 307 (69)
Travellers without pre‑travel visit, n (%) (n = 429) 246 (57)
Region of exposure, n (%)
 Sub‑Saharan Africa 420 (95)
 Southeast Asia 10 (2)
 South Central Asia 4 (1)
 Caribbean 3 (1)
 North Africa 2 (<1)
 Oceania 2 (<1)
 Central America 2 (<1)
 South America 1 (<1)
Reason for travel, n (%)
 VFR 187 (42)
 Business 133 (30)
 Tourism 80 (18)
 Missionarya 33 (7)
 Military 7 (2)
 Student 3 (1)
 Planned medical care 1 (<1)
Plasmodium species, n (%) (n = 124)
 P. falciparum 120 (97)
 P. vivax 2 (2)
 P. ovale 0 (0)
 P. malariae 2 (2)
Median trip duration, days (IQR) 31 (18–66)
Median days between return and presenting to a site (IQR) 11 (5–16)
Hospitalized, n (%) 402 (91)
Cerebral malaria (n) 14
Deaths (n) 12
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traveller groups, consistent with other published reports 
[5]. This may be due to a lack of risk awareness among 
VFRs due to previous residence in a malaria-endemic 
area, financial barriers that prevent VFRs from obtain-
ing a pre-travel visit or filling prescriptions for pro-
phylactic medications, cultural or language barriers 
in accessing pre-travel care, adoption of local health-
related behaviour during their trip, or travel to areas 
with high transmission intensity, sometimes for an 
extended time or with little advance notice [11, 17–19]. 
A Global TravEpiNet analysis of pre-travel healthcare 
visits that found VFRs were more likely than non-VFRs 
to visit malaria-endemic countries [20]. In this analy-
sis, VFRs were most frequently infected with P. falcipa-
rum; this finding is consistent with surveillance findings 
from Europe, including the UK, where more than 80% 
of imported P. falciparum malaria was among VFRs 
[21, 22]; this finding is likely due to a high frequency of 
travel to West Africa. Preventing malaria (particularly 
severe malaria caused by P. falciparum) among VFRs is 
best if done proactively; this includes increasing malaria 
awareness, promoting pre-travel visits and inquiring 
about future travel plans [23]. Diminishing the burden 
of imported malaria among travellers to sub-Saharan 
Africa and VFRs must be a continued focus of malaria 
prevention efforts. Diminishing this burden will also 
prevent re-introduction of malaria to locations that have 
achieved malaria elimination.
This is the largest analysis to date describing character-
istics of child travellers with malaria from North America 
and Europe [24]. One in 10 children treated at GeoSenti-
nel clinics had severe malaria and children <5 years of age 
accounted for almost half of all severe paediatric cases. 
Previous studies demonstrated that children account 
for 15–20% of all imported malaria cases, and approxi-
mately 5–10% of children have illness classified as severe, 
according to WHO criteria [24]; up to one-third of chil-
dren surviving severe or cerebral malaria will have persis-
tent neurocognitive impairment [25]. Approximately 80% 
of children diagnosed with malaria were VFRs, and expo-
sure was most common in sub-Saharan Africa. Appropri-
ate preventive care and chemoprophylaxis targeting child 
VFRs is crucial to help limit travel-related morbidity in 
this group [24, 26], particularly when travelling to regions 
where P. falciparum predominates. Prevention efforts 
must include encouraging pre-travel visits for both adults 
and their children and providing training and education 
to paediatricians who may be the only healthcare pro-
vider a child sees before travelling. Improved identifica-
tion of potential child travellers and better adherence 
to preventive measures is imperative to prevent malaria 
morbidity and mortality in this population.
The majority of severe malaria infections was caused by 
P. falciparum in both adults and children in this analysis, 
consistent with both WHO reports [12] and US traveller 
surveillance findings from 2014 demonstrating that 83% 
of severe cases imported to the USA were P. falciparum 
[5]. Almost all severe malaria infections were acquired in 
Sub-Saharan Africa, and most frequently among VFRs. 
A recent multicentre European study describes a simi-
lar pattern of geographic exposure and reason for travel 
among travelers with severe malaria to this current study, 
but in comparison, report a smaller percentage of travel-
ers ≤18 years with severe malaria (5% vs 7% respectively) 
[27]. The reason for this difference is unknown, but may 
be a result of small numbers in each study’s cohort.
Most military travellers with P. vivax in this analysis 
were French, and 58% were exposed to malaria in French 
Guiana. A possible explanation for this finding is the 
increasing proportion of vivax malaria found in French 
Guiana and an increase in French military missions to the 
country from 1998 to 2008 [28]. However, there is report-
ing bias, since the Marseille GeoSentinel site contributed 
the greatest number of records in this analysis, resulting 
in a large proportion of travellers returning from French-
speaking countries.
One in 10 travellers with malaria traveled for 1  week 
or less, and 40% of short-term travellers with a species 
diagnosis had P. vivax. Short-duration travel is often 
viewed as low risk and, in some cases, prophylaxis may 
be declined or not recommended. However, malaria 
remains a risk even for short stays in an endemic area, 
and therefore a risk–benefit evaluation of malaria chemo-
prophylaxis should be considered. A limitation regarding 
acquiring clinical data from short-term travellers with P. 
vivax or P. ovale, is their infection cannot be definitively 
linked to the most recent travel.
The highest proportion of completed pre-travel visits 
was among travellers diagnosed with P. ovale. Although 
the reason for this finding is unclear, it may be from 
greater pre-travel preparation for longer-duration trips, 
given that travellers with P. ovale had the longest median 
trip duration (55  days). It may also be due to a larger 
proportion of travellers seeking pre-travel health advice 
before travelling to Africa, where P. ovale is concentrated. 
It is also possible that compliance with chemoprophy-
laxis may prevent symptomatic primary infections with 
P. ovale, but not relapses weeks to months later. This lat-
ter hypothesis is further supported by the finding that 
travellers with P. ovale had an almost 2-month delay 
between returning from travel and visiting a GeoSentinel 
site. However, although both P. ovale and P. vivax have 
longer median duration between return and present-
ing to a GeoSentinel site and both may have a delayed 
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presentation due to hypnozoite reactivation, these find-
ings did not hold for P. vivax, suggesting the presence of 
confounders for this hypothesis.
This analysis of GeoSentinel surveillance data has sev-
eral limitations. Given the specialized nature of the sites 
that comprise the surveillance system, these data may not 
be representative of all travellers with malaria. GeoSen-
tinel is not population-based, so malaria rates and risks 
cannot be determined. GeoSentinel does not routinely 
collect information regarding malaria chemoprophylaxis, 
including the medication taken and compliance; as such, 
chemoprophylaxis appropriateness or traveller adher-
ence or identify the specific reasons why these travellers 
became infected cannot be assessed. Nevertheless, given 
the low proportion of receipt of pre-travel counseling 
among travellers diagnosed with malaria in this analysis, 
preparation for travel to malaria-endemic regions was 
likely inadequate. Severe malaria may not be adequately 
captured in GeoSentinel, as not all sites have in-patient 
treatment capabilities and diagnosis relies on clinical iden-
tification and provider discretion. Similarly, death is not 
well-recorded through GeoSentinel surveillance, reflected 
in the absence of deaths reported among patients with 
cerebral malaria and the absence of species determina-
tion. Data are collected from a single time point, and may 
not capture a later death, therefore a case fatality rate can-
not be calculated. More than 400 travellers did not have 
Plasmodium species information available in GeoSenti-
nel; the entry of a specific Plasmodium species was not 
required prior to 2017, resulting in confirmed malaria 
without a Plasmodium species diagnosis. Also, the lack 
of diagnostic methodology information collected in Geo-
Sentinel does not allow for independent validation of spe-
cies diagnoses or mixed-species identifications; although 
microscopy is the gold standard for malaria diagnosis in 
most centres [1], mixed-species infections may be over-
looked or incorrectly characterized [29, 30]. Despite these 
limitations, GeoSentinel is the largest surveillance sys-
tem providing clinical data on travellers, and contributes 
valuable data on the epidemiology of infectious diseases 
acquired during international travel and migration.
Conclusions
Despite general improvements in control programmes, 
malaria continues to cause serious illness in international 
travellers, particularly VFRs. By identifying the char-
acteristics of travellers with malaria, prevention efforts 
may be enhanced, such as proactively asking patients 
about upcoming travel during routine healthcare con-
tacts, ensuring access to appropriate chemoprophylaxis, 
increasing risk awareness, and reinforcing the need 
for prevention measures among higher-risk travellers, 
including children.
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